Novartis today announced that it has entered into a development and licensing agreement with Biological E Limited (BioE), a biopharmaceutical company based in India, for two vaccines to protect against typhoid and paratyphoid fevers. The agreement advances the Novartis goal to deliver accessible and affordable vaccines that address unmet medical need in endemic regions.
Preventing typhoid can change communities. The primary goal of the Coalition is to define the barriers for the adoption of typhoid vaccines in the communities where they are needed most and the key activities that are needed to overcome them.
The Vaccine Advocacy and Education program at Sabin is dedicated to reducing the burden of preventable diseases by bringing together key stakeholders and leaders in government, private sector and civil society in order to foster cooperation, share information and best practices, and develop improved vaccine policy and access.